The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial

The aim of this review was to present the recently published results of ODYSSEY OUTCOMES trial and discuss the clinical perspective of these data. Patients with acute coronary syndrome are at very high risk of recurrent ischemic cardiovascular complications, especially during the first year after th...

Full description

Bibliographic Details
Main Author:	Yu. A. Karpov
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2019-01-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	alirocumab pcsk9 inhibitors lipid-lowering treatment hypercholesterolemia acute coronary syndrome major adverse cardiovascular events
Online Access:	https://www.rpcardio.com/jour/article/view/1810

Similar Items

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
by: Remo H. M. Furtado, et al.
Published: (2020-02-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01)

PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
by: Lοukianos S. Rallidis, et al.
Published: (2016-03-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020-12-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art
by: Gabriella Iannuzzo, et al.
Published: (2021-04-01)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
by: Brian Tomlinson, et al.
Published: (2021-04-01)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
by: Alex Smith, et al.
Published: (2021-08-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

PCSK9 monoclonal antibodies: An overview
by: Rasha Kaddoura, et al.
Published: (2020-01-01)

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
by: Natalia Pauli, et al.
Published: (2020-07-01)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments
by: Kiley, Mark E.
Published: (2018)

Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience
by: Roberto Scicali, et al.
Published: (2020-11-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
by: Edyta Kinga Prokop, et al.
Published: (2019-04-01)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
by: Laurenz T. Fischer, et al.
Published: (2021-04-01)

Patients With <italic toggle="yes">LDLR</italic> and <italic toggle="yes">PCSK9</italic> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
by: Takahito Doi, et al.
Published: (2021-02-01)

Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
by: Khalid Al-Waili, et al.
Published: (2013-01-01)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
by: Li Li, et al.
Published: (2018-09-01)

The Functional Characterization of PCSK9's Binding Interactions with LDL and the LDL Receptor
by: Matyas, Angela
Published: (2020)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020-01-01)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
by: Ye-Xuan Cao, et al.
Published: (2019-11-01)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
by: Dirk Müller-Wieland, et al.
Published: (2017-05-01)

Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
by: Alessandro Di Minno, et al.
Published: (2021-08-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
by: Dipti Athavale, et al.
Published: (2018-10-01)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
by: Tsuyoshi Yamamoto, et al.
Published: (2012-01-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
by: Zhe Liang, et al.
Published: (2021-04-01)

Cannot write session to /tmp/vufind_sessions/sess_11unnfa0geh8q6kn94impvl7br